



Kezar Life Sciences to Present at the William Blair Biotech Focus Conference

July 7, 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 7, 2022-- [Kezar Life Sciences, Inc.](#) (Nasdaq: [KZR](#)), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Noreen Roth Henig, M.D., Chief Medical Officer, will participate in a panel called "*Developing Therapies Against Novel Targets in Autoimmune Diseases*" at the William Blair Biotech Focus Conference in New York, NY. The panel will be held in person on Wednesday, July 13, 2022, at 11:00 am ET.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company's platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220707005143/en/): <https://www.businesswire.com/news/home/20220707005143/en/>

Investor

Gitanjali Jain
Vice President, Investor Relations and External Affairs
650-269-7523
gjain@kezarbio.com

Media

Liza Sullivan
Argot Partners
212-600-1902
kezar@argotpartners.com

Source: Kezar Life Sciences, Inc.